Clinical Trial Update: Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP) [Phase 1]

View source ↗

Summary

Phase 1 safety study of EF-022 in adults with recurrent respiratory papillomatosis; the trial status is listed but not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Papillomatosis

Drugs mentioned

• EF-022

Snippet

Sponsor: Efranat Ltd. | Conditions: Recurrent Respiratory Papillomatosis | Phase 1 | Status: UNKNOWN